Suppr超能文献

病毒性肝炎

Viral Hepatitis

作者信息

Wiktor Stefan Z

Abstract

Viral hepatitis is caused by five distinct viruses (hepatitis A, B, C, D, and E), which have different routes of transmission and varying courses of disease (table 16.1). According to the Global Health Estimates, deaths from acute and chronic hepatitis in 2012 were the tenth leading cause of death and the sixteenth leading cause of disability. In 2013, an estimated 1.45 million persons (95 percent uncertainty interval 1.38 million to 1.54 million) died from viral hepatitis; this estimate includes deaths due to acute hepatitis, as well as hepatitis-related liver cancer and cirrhosis (Stanaway and others 2016). Furthermore, while deaths from infectious diseases such as HIV/AIDS, malaria, and tuberculosis are decreasing, deaths from hepatitis increased by 63 percent between 1990 and 2013. Most (96 percent) hepatitis deaths are caused by hepatitis B virus (HBV) and hepatitis C virus (HCV)—these two viruses cause chronic, lifelong infection resulting in progressive liver damage leading to cirrhosis and hepatocellular carcinoma (figure 16.1). The burden of hepatitis infection is not equally distributed globally. Mortality rates from hepatitis are highest in West Africa and parts of Asia; in absolute numbers, East Asia and South Asia account for the greatest number of people dying from hepatitis—51 percent of the total number of deaths. Effective interventions exist to prevent transmission of viral hepatitis (table 16.2). Safe and effective vaccines have been developed to prevent hepatitis A, B, and E, and protection from hepatitis B infection by immunization also prevents hepatitis D. Hepatitis B and C chronic infections can be treated effectively. The new direct acting antiviral (DAA) medicines for hepatitis C can cure more than 90 percent of those with chronic infection with a two to three month course of treatment. Hepatitis C treatment could also reduce hepatitis C transmission because people who have been cured do not transmit the infection. There is no cure for chronic hepatitis B, but effective antiviral treatments can suppress viral replication and prevent disease progression.

摘要

病毒性肝炎由五种不同病毒(甲型、乙型、丙型、丁型和戊型肝炎病毒)引起,它们具有不同的传播途径和病程(表16.1)。根据全球卫生估计,2012年急性和慢性肝炎导致的死亡是第十大死亡原因和第十六大致残原因。2013年,估计有145万人(95%不确定区间为138万至154万)死于病毒性肝炎;这一估计包括急性肝炎导致的死亡以及与肝炎相关的肝癌和肝硬化(斯塔纳韦等人,2016年)。此外,虽然艾滋病病毒/艾滋病、疟疾和结核病等传染病导致的死亡人数在减少,但1990年至2013年间,肝炎导致的死亡人数增加了63%。大多数(96%)肝炎死亡由乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)引起——这两种病毒会导致慢性终身感染,进而导致肝脏进行性损伤,最终发展为肝硬化和肝细胞癌(图16.1)。肝炎感染的负担在全球分布不均。肝炎死亡率在西非和亚洲部分地区最高;从绝对数字来看,东亚和南亚死于肝炎的人数最多,占死亡总数的51%。现已有有效的干预措施来预防病毒性肝炎的传播(表16.2)。已研发出安全有效的疫苗来预防甲型、乙型和戊型肝炎,通过免疫预防乙型肝炎感染也可预防丁型肝炎。乙型和丙型肝炎慢性感染可以得到有效治疗。用于治疗丙型肝炎的新型直接抗病毒(DAA)药物在两到三个月的疗程中可治愈超过90%的慢性感染者。丙型肝炎治疗还可减少丙型肝炎传播,因为已治愈的人不会传播感染。慢性乙型肝炎无法治愈,但有效的抗病毒治疗可抑制病毒复制并预防疾病进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验